CompletedNot Applicable

The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study

United States477 participantsStarted 2012-10

Plain-language summary

The aim is to propose and prospectively validate a diagnostic approach and model for prediction of mucinous versus non-mucinous, and malignant versus non-malignant pancreatic cysts using a combination of clinical, radiologic, and biomarker characteristics.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients age 18 years and older
✓. Referred for assessment of one or more pancreatic cyst.

Exclusion criteria

✕. Medically ill patients with ASA class 4 or greater.
✕. History of chronic kidney disease with a serum creatinine \> 2.0 mg/dl or estimated glomerulofiltration rate (eGFR) \< 30 ml/min, dialysis patients, acute renal failure, cirrhosis of the liver, chronic hepatitis, prior nephrectomy or kidney or liver transplantation.
✕. History of moderate (generalized hives) or severe (facial swelling, airway reaction) reaction to intravenous radiographic contrast material.
✕. History of obstruction in the upper GI tract such as esophageal or pyloric stricture, which would not allow passage of an endoscope.
✕. Bleeding diathesis (clotting problems) or a history of thrombocytopenia (low platelet count \<50,000).
✕. Inability to provide informed consent.
✕. Pregnancy or lactation.

What they're measuring

Prevalence and incidence of malignant pancreatic cysts

Timeframe: 3-6 years

Trial details

NCT IDNCT01202136

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-01

View on ClinicalTrials.gov More Pancreatic Cysts trials